In this study, the combination of anti-PD-1 ICB treatment and RIT utilizing the beta emitter 177Lu radiolabeled h8C3 showed a significant reduction in tumor doubling time, and notable effect on overall survival when compared to any monotherapy (Table 1). Here, PDCD1 is linked to neoplasm.